No link to cardiac valvulopathy was seen in cabergoline treated patients
<p><strong>Objective:</strong> To evaluate the association between use of cabergoline in patients with prolactinoma and risk of developing clinically relevant cardiac valvular disease.</p> <p><strong>Method:</strong> This was a descriptive cross sectional st...
Päätekijät: | K Dharshini, Noel Somasundaram, HMDPK Senevirathna, S Raj Kumar |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
Sri Lanka College of Endocrinologists
2012-10-01
|
Sarja: | Sri Lanka Journal of Diabetes Endocrinology and Metabolism |
Aiheet: | |
Linkit: | https://sjdem.sljol.info/articles/4775 |
Samankaltaisia teoksia
-
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Tekijä: Shruti Khare, et al.
Julkaistu: (2017-01-01) -
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
Tekijä: Annabelle G Hayes, et al.
Julkaistu: (2023-01-01) -
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
Tekijä: Youngki Lee, et al.
Julkaistu: (2014-09-01) -
Spontaneous reduction of prolactinoma post cabergoline withdrawal
Tekijä: Sampath Kumar Venkatesh, et al.
Julkaistu: (2012-01-01) -
The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
Tekijä: Larisa Dzeranova, et al.
Julkaistu: (2016-11-01)